TRIANA Biomedicines Enters into a Research Collaboration with Johnson & Johnson to Identify Oncology Molecular Glue Degraders

Lexington, MA – January 6, 2026 – TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced a research collaboration with Johnson & Johnson* to advance the discovery of important molecular glue targets in oncology.

The collaboration aims to advance next-generation molecular glue degraders by applying TRIANA’s proprietary molecular glue discovery platform to targets that have been inadequately targeted or considered undruggable. Molecular glues represent a potentially transformative modality that enables selective elimination of disease-driving proteins, opening the door to more accessible, durable, and differentiated therapeutics for patients.

“This collaboration agreement underscores TRIANA’s unique ability to discover promising therapeutics against hard-to-drug targets,” said Dr. Patrick Trojer, President and CEO of TRIANA. “We believe our molecular-glue discovery engine represents an important and emerging drug modality—one with the potential to bring meaningful benefits to cancer patients. The strategic partnership brings together unique capabilities from both companies in the pursuit of successfully identifying cancer targeted molecular glue degraders.”

*Legal entity: Janssen Pharmaceutica NV

About TRIANA Biomedicines, Inc.

TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts and focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile cancer targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.

Contact

IR@trianabio.com